Rosuvastatin inhibited expression of vascular proliferative factors including EGF, VEGF and PDGF may have an antitumor effect, in addition to its antihyperlipidemic effect, against HCC associated with NASH. Here, VEGFA is linked to metabolic dysfunction-associated steatohepatitis.